Medicine
Inmazeb 483.3 mg/483.3 mg/483.3 mg per 14.5 mL injection
Inmazeb 483.3 mg/483.3 mg/483.3 mg per 14.5 mL injection is a prescription medicine containing Atoltivimab, Maftivimab and Odesivimab for intravenous use, marketed by Regeneron Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store INMAZEB vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original…
Key facts
- Active ingredient (INN)
- Atoltivimab, Maftivimab and Odesivimab
- Brand
- Inmazeb
- Strength
- 483.3 mg/483.3 mg/483.3 mg per 14.5 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 14.5 mL
- Marketing authorisation holder
- Regeneron Pharmaceuticals
- Manufacturer
- Regeneron Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store INMAZEB vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake. Lactated Ringer's Injection, USP Store at room temperature up to 25°C (77°F) for no more than 4 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for no more than 4 hours. Store the diluted INMAZEB solution as specified according to Table 12 below.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 July 2021
- Identifiers
- RxCUI 2461536, 2461539, 2571682 +1DailyMed set ID 0536b6fe-6fe5-4fd6-8cc6-1b481945c1faNDC 61755-019Application BLA761169
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 14.5 mL in 1 vial, single-dose | 61755-019-01 | Regeneron Pharmaceuticals | 29 July 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 14 October 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Atoltivimab, Maftivimab and Odesivimab
Clinical summary
Atoltivimab, Maftivimab and Odesivimab is a fixed-dose combination medicine indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother, among other approved uses. MedsAcross supplies Atoltivimab, Maftivimab and Odesivimab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Atoltivimab, Maftivimab and OdesivimabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Inmazeb prescribing information (Regeneron Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Inmazeb 483.3 mg/483.3 mg/483.3 mg per 14.5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.